Virbac SA

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: FR0000031577
EUR
339.00
-1.5 (-0.44%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Virbac SA stock-summary
stock-summary
Virbac SA
Pharmaceuticals & Biotechnology
Virbac SA is a France-based veterinarian pharmaceutical company that specializes in the development and production of vaccines and medicines for domestic animals and livestock. Its production centers are located in France, Australia, the United States, Mexico, Vietnam, Brazil and South Africa. Its development efforts focus mainly on formulating drugs designed to prevent or cure certain animal diseases. Its product portfolio encompasses pet medications such as pest control drugs, vaccines, antibiotics, anesthetics, anti-inflammatory drugs, mouth/dental care products, ophthalmologic and dermatological products intended for dogs, cats, horses, birds and rodents, as well as livestock medications including pest control drugs and antibiotics intended for cattle, sheep, pigs and poultry. It also offers food and electronic identification chips for pets.
Company Coordinates stock-summary
Company Details
13eme rue LID, Bp 27, Carros Cedex , CARROS None : 06510
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 1 Foreign Institutions (0.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Marie-Helene Dick
Chairwoman of the Supervisory Board
Mr. Pierre Madelpuech
Vice Chairman of the Supervisory Board
Mr. Olivier Bohuon
Independent Member of the Supervisory Board - Representative of OJB Conseil
Mr. Philippe Capron
Independent Member of the Supervisory Board
Mr. Cyrille Petit
Independent Member of the Supervisory Board - representative of Cyrille Petit Conseil
Ms. Sylvie Gueguen
Member of the Supervisory Board - Employee Representative
Ms. Solene Madelpuech
Member of the Supervisory Board
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
166 Million
(Quarterly Results - Dec 2012)
Net Profit:
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

EUR 2,995 Million ()

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.41%

stock-summary
Debt Equity

0.16

stock-summary
Return on Equity

12.82%

stock-summary
Price to Book

2.81